MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson’s program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and a strategic collaboration with Hologen Limited to develop Phase 3 clinical trials for AAV-GAD to treat Parkinson’s disease. The company was incorporated in 2015 and is based in New York, New York.
Gene Therapy Pionee | MeiraGTx's diverse pipeline spans treatments for xerostomia, X-linked retinitis pigmentosa, and Parkinson's disease, positioning it as a leader in gene therapy innovation |
Financial Fortification | Explore how MeiraGTx secured $50 million in equity financing, including a significant $30 million investment from pharmaceutical giant Sanofi, bolstering its research capabilities |
Regulatory Milestones | Learn about MeiraGTx's crucial FDA alignment for its xerostomia treatment, potentially supporting a Biologics License Application by 2026 and accelerating market entry |
Market Valuation | Analyst price targets range from $11 to $36, suggesting significant upside potential despite the stock's current "Speculative Risk" qualifier and recent price target adjustment |
Metrics to compare | MGTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMGTXPeersSector | |
---|---|---|---|---|
P/E Ratio | −4.2x | −1.0x | −0.5x | |
PEG Ratio | 0.10 | −0.01 | 0.00 | |
Price/Book | 9.1x | 1.0x | 2.6x | |
Price / LTM Sales | 18.6x | 8.8x | 3.0x | |
Upside (Analyst Target) | 220.9% | 547.1% | 56.4% | |
Fair Value Upside | Unlock | 23.9% | 9.9% | Unlock |